CADTH

CADTH REIMBURSEMENT REVIEW

Stakeholder Feedback on Draft Recommendation

RIPRETINIB (Qinlock)

(Medison Pharma Canada Inc.)

Indication: For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.

April 14, 2022

CADTH Reimbursement Review

Feedback on Draft Recommendation

Stakeholder information	
CADTH project number	PC0265
Name of the drug and Indication(s)	Ripretinib for GIST
Organization Providing Feedback	PAG

1. Recommendation revisions Please indicate if the stakeholder requires the expert review committee to reconsider or clarify its recommendation.		
Request for Reconsideration	**Major revisions:** A change in recommendation **category** or patient **population** is requested	☐
	Minor revisions: A change in reimbursement **conditions** is requested	☐
No Request for Reconsideration	**Editorial revisions:** Clarifications in recommendation **text** are requested	X
	No requested revisions	☐

2. Change in recommendation category or conditions Complete this section if major or minor revisions are requested
None.

3. Clarity of the recommendation Complete this section if editorial revisions are requested for the following elements
a) Recommendation rationale
In Table 2. Responses to Questions from the Drug Programs, under the heading “Considerations for discontinuation of therapy,” PAG is requesting to remove the following text” pERC noted that dosing 150 mg ripretinib orally twice daily is not approved by Health Canada. Hence, pERC cannot recommend such as use.”
b) Reimbursement conditions and related reasons
None.
c) Implementation guidance
None.

CADTH

CADTH Reimbursement Review
Feedback on Draft Recommendation

Stakeholder information	
CADTH project number	PC0265
Brand name (generic)	QINLOCK™ (ripretinib)
Indication(s)	For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
Organization	Medison Pharma Canada Inc.
Contact information[a]	[redacted]

Stakeholder agreement with the draft recommendation		
1. Does the stakeholder agree with the committee's recommendation.	Yes	☒
	No	☐

Medison Pharma Canada Inc. (Medison) agrees with CADTH's draft recommendation for ripretinib.

Medison also recognizes feedback received from the provincial advisory group (PAG), clinicians, and patient advocacy groups who have provided input and have all indicated that the reimbursement of ripretinib would fulfill a significant unmet need for a new treatment for adult patients with advanced GIST who have received prior treatment with imatinib, sunitinib, and regorafenib.

Expert committee consideration of the stakeholder input		
2. Does the recommendation demonstrate that the committee has considered the stakeholder input that your organization provided to CADTH?	Yes	☒
	No	☐

Clarity of the draft recommendation		
3. Are the reasons for the recommendation clearly stated?	Yes	☒
	No	☐
4. Have the implementation issues been clearly articulated and adequately addressed in the recommendation?	Yes	☒
	No	☐
5. If applicable, are the reimbursement conditions clearly stated and the rationale for the conditions provided in the recommendation?	Yes	☒
	No	☐

[a] CADTH may contact this person if comments require clarification.